長效抗逆轉錄病毒藥物市場按產品類型、作用機制、治療領域、給藥頻率、治療方法、患者類型和分銷管道分類－全球預測，2026-2032年

2025 年長效抗 HIV 藥物市值為 3.7686 億美元，預計到 2026 年將成長至 4.451 億美元，年複合成長率為 20.43%，到 2032 年將達到 13.8464 億美元。

關鍵市場統計數據
基準年 2025	3.7686億美元
預計年份：2026年	4.451億美元
預測年份 2032	13.8464億美元
複合年成長率 (%)	20.43%

本文簡要概述了臨床、監管和醫療保健服務方面的變化，這些變化將重新定義長效抗逆轉錄病毒療法的依從性和治療模式。

長效抗逆轉錄病毒藥物的出現，標誌著臨床醫生、支付方和患者在愛滋病預防和慢性病管理方面取得了突破性進展。從緩釋注射劑到皮下植入，這些治療方法旨在解決依從性問題，減少給藥頻率，並提高不同患者群體中病毒的持續抑制率。臨床醫師不僅關注這些治療方案的療效，也日益重視它們如何重塑治療路徑、推廣計畫以及病患參與長期治療的情況。

製劑技術、醫療設備和系統的最新創新如何從根本上改變了長效愛滋病治療的治療路徑

近年來，抗愛滋病毒療法領域經歷了數次變革性變化，這主要得益於製劑科學和器械工程的進步，以及對以患者為中心的治療效果的日益重視。長效候選藥物目前採用可生物分解和不可生物分解的植入平台，以及肌肉注射和皮下注射製劑，從而實現了以往無法達到的多種給藥間隔。這些技術進步正推動給藥間隔從每月一次延長至每兩個月一次甚至每三個月一次，進而改變治療方法的設計和實施方式。

評估2025年關稅調整如何重塑長效HIV藥物生態系統的採購、製造地選擇和商業合約策略。

2025年的政策環境引入了一系列關稅調整，對整個醫藥供應鏈和商業策略產生了顯著的下游影響。關稅變化影響了進口原料、專用給藥裝置以及長效製劑中使用的某些中間體的成本基礎。隨著上游採購成本的波動，製造商重新評估了籌資策略和近岸外包方案，以降低貿易政策波動帶來的風險，同時維持可預測的生產計畫。

全面的細分分析揭示了產品類型、作用機制、治療標靶、給藥間隔、通路、患者群體和治療方法的選擇將如何影響產品開發和商業化。

長效抗HIV產品的細分分析揭示了不同的臨床和商業性路徑，每條路徑都需要專門的研發和上市策略。植入和注射劑產品類型的區別導致了不同的考慮因素。對於植入，可生物分解基質與不可生物分解基質的選擇會影響移除程序和裝置監測；而對於注射劑而言，需要針對肌肉或皮下給藥進行製劑最佳化，這會影響基於場所或基於社區的給藥模式。按作用機制進行細分錶明，整合酶抑制劑、蛋白酶抑制劑和逆轉錄酶抑制劑各自具有獨特的抗藥性特徵、相互作用風險和製劑限制，這些都會影響聯合治療治療策略與單藥治療策略的發展。

區域性趨勢和實施考量將決定長效抗病毒干預措施在不同醫療保健系統中的監管、採用和推廣方式。

長效抗逆轉錄病毒療法的採納和部署在各地區的趨勢反映了不同的衛生系統結構、監管路徑和流行病學重點。在美洲，對診所基礎設施的投資以及支付方對新型給藥方式的支持意願正在加速都市區的推廣應用，同時公共衛生計畫正致力於將長效療法納入現有的預防和治療策略。在歐洲、中東和非洲地區，獲取途徑則呈現分化趨勢。儘管存在監管協調努力和國家籌資策略，但醫療服務能力差異巨大，這不僅為精準部署提供了機遇，也為公平分配帶來了挑戰。

開發商、設備合作夥伴和製造專家之間的策略競爭格局和合作框架將決定產品部署動能和商業化準備。

該領域的競爭與合作格局正由眾多參與者共同塑造，其中包括成熟的製藥公司、專業的生物技術創新者以及專注於藥物遞送平台的醫療器材製造商。主要企業將深厚的抗病毒藥理學知識與緩釋技術能力相結合，藥物研發企業與醫療器材工程師之間建立策略聯盟以加速聯合開發已成為常態。對製劑科學的投入，尤其是在確保可預測的釋放曲線和最大限度減少注射部位及植入相關併發症，仍然是競爭對手之間關鍵的差異化因素。

為確保供應鏈的韌性、與支付方合作以及部署以患者為中心的長效治療方法，開發人員和商業領導者應制定可操作的跨職能優先事項。

產業領導者應推動一系列切實可行的舉措，將科學進步轉化為持續的臨床影響和商業性成功。首先，應優先制定整合開發計劃，從早期階段就將製劑技術、器械設計和監管策略協調一致，以最大限度地減少後期變更並簡化核准流程。其次，應投資於靈活的生產製造和雙源籌資策略，以增強因應政策引發的供應中斷的能力，並支持區域上市計畫。第三，應設計差異化的患者支持模式，使其能夠適應不同的給藥頻率和給藥環境，確保成人和兒童患者群體都能獲得量身定做的教育和監測。

嚴謹的質性、以文獻為基礎的調查方法，整合了相關人員訪談、臨床文獻和政策分析，以得出可操作的策略見解和限制。

本分析的研究結合了最新臨床文獻、監管指導文件和公共聲明的系統性回顧，以及與研發、生產和支付方等各領域專家的專案諮詢。主要資訊來源包括對具有長效製劑給藥經驗的臨床醫生、專注於醫療設備-藥物組合的監管事務專家以及負責區域製造地的供應鏈高管的訪談。這些質性研究輔以已發表的安全性和藥物動力學研究、監管文件和產品生命週期資訊披露的次要分析，以確保臨床證據與策略意義相符。

本報告將臨床前景與系統層面的必要性相結合，闡述了產業界和醫療衛生系統之間的合作努力將如何決定持續治療方法在現實世界中的成功。

長效抗愛滋病毒療法正在重塑臨床策略，其提供的全新治療方法能夠提高患者依從性，減少就診次數，並在整個預防和治療人群中持續發揮療效。製劑創新、醫療設備的不斷發展以及醫保報銷模式的轉變，共同創造了機遇，同時也帶來了挑戰。製造商必須平衡藥物的藥理性能和給藥的便捷性，而醫療系統則必須調整基礎設施和支付方結構，以支持更廣泛的應用。無論在哪個地區，制定符合當地實際情況的推廣策略對於將臨床療效轉化為真正的公共衛生效益至關重要。

目錄

第1章：序言

第2章調查方法

• 研究設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查前提
• 調查限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會地圖
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的長效抗HIV藥物市場

• 植入
  • 可生物分解
  • 不可生物分解
• 注射
  • 肌肉內注射
  • 皮下注射

9. 依作用機轉分類的長效抗HIV藥物市場

• 整合酶抑制劑
• 蛋白酶抑制劑
• 逆轉錄酶抑制劑

第10章：依治療領域分類的長效抗HIV藥物市場

• 預防
• 治療

11. 依給藥頻率分類的長效抗HIV藥物市場

• 每隔一個月
• 每月一次
• 季刊

12. 依治療方法的長效抗HIV藥物市場

• 聯合治療
  • 三聯聯合治療
  • 雙藥聯合治療
• 單藥治療

第13章：依病患類型分類的長效抗HIV藥物市場

• 成人版
• 兒童

第14章 長效抗愛滋病藥物市場（依通路分類）

• 離線
• 線上

第15章 各地區長效抗愛滋病毒藥物市場

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第16章：按組別分類的長效抗HIV藥物市場

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第17章 各國長效抗愛滋病毒藥物市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

18. 美國長效抗愛滋病毒藥物市場

第19章 中國的長效抗愛滋病藥物市場

第20章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Accord Healthcare Inc.
• Amneal Pharmaceuticals, Inc.
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Genentech, Inc.
• Gilead Sciences, Inc.
• Hetero Labs Limited
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Mylan NV
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Theratechnologies Inc.
• Viatris Inc.
• ViiV Healthcare Limited

The Long-acting Anti-HIV Drugs Market was valued at USD 376.86 million in 2025 and is projected to grow to USD 445.10 million in 2026, with a CAGR of 20.43%, reaching USD 1,384.64 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 376.86 million
Estimated Year [2026]	USD 445.10 million
Forecast Year [2032]	USD 1,384.64 million
CAGR (%)	20.43%

A concise orientation to the clinical, regulatory, and care delivery shifts sparked by long-acting anti-HIV therapies that redefine adherence and treatment paradigms

The advent of long-acting anti-HIV therapeutics represents a pivotal evolution in how clinicians, payers, and patients approach both prevention and chronic management of HIV. These modalities-ranging from extended-release injectables to subdermal implants-are designed to address adherence challenges, reduce dosing frequency, and improve sustained viral suppression in diverse patient populations. Clinicians are increasingly evaluating these options not only on efficacy but on how they reshape care pathways, outreach programs, and long-term therapeutic engagement.

As development programs move forward, stakeholders across the ecosystem are adapting clinical protocols, supply chains, and patient education strategies to accommodate devices and formulations that require distinct administration settings and monitoring. Regulatory authorities are clarifying requirements for pharmacokinetic bridging and device-related safety, prompting sponsors to embed robust real-world evidence collection early in development. Payors and health systems are beginning to model the operational implications of these therapies, considering administration costs, training burdens, and potential reductions in downstream morbidity.

Taken together, these dynamics are shifting the conversation from incremental product improvement toward system-level transformation, where long-acting options are considered instruments of care redesign. The following sections explore the technological, commercial, and policy inflection points that are driving adoption, segmentation dynamics, regional variation, and the strategic actions companies should prioritize.

How recent formulation, device and systemic innovations have catalyzed a fundamental reorientation of treatment pathways for long-acting anti-HIV therapies

In recent years the landscape for anti-HIV treatment has experienced several transformative shifts driven by advances in formulation science, device engineering, and an intensified focus on patient-centric outcomes. Long-acting drug candidates now leverage biodegradable and non-biodegradable implant platforms as well as intramuscular and subcutaneous injectable formulations, enabling a range of administration cadences that were previously unattainable. These technical capabilities have opened routes for extending intervals between doses from monthly to bi-monthly and even quarterly schedules, which in turn are changing how therapeutic regimens are conceived and operationalized.

Concurrently, mechanistic innovation across integrase inhibitors, protease inhibitors, and reverse transcriptase inhibitors has deepened the pharmacologic toolkit available to developers. Combination regimens that include two- or three-drug approaches are being reconsidered through the lens of long-acting delivery, with attention to drug-drug compatibility, release kinetics, and sustained therapeutic windows. The shift toward fixed long-acting regimens has prompted clinical investigators to explore new endpoints and adherence metrics while encouraging manufacturers to pursue device-drug co-development strategies.

Policy and payer environments are also evolving, with reimbursement discussions now encompassing administration settings such as hospital pharmacies, retail outlets, and emerging online pharmacy models for coordinating home administration. Together, these technological and systemic shifts are not just introducing new products but catalyzing a redefinition of patient journeys, clinical workflows, and commercial models across the broader HIV care continuum.

An assessment of how 2025 tariff adjustments reshaped sourcing, manufacturing footprint decisions, and commercial contracting strategies across the long-acting anti-HIV ecosystem

The policy landscape entering 2025 introduced a set of tariff adjustments that have created palpable downstream effects across pharmaceutical supply chains and commercial strategies. Tariff changes influenced the cost base for imported raw materials, specialized delivery devices, and certain intermediate components used in long-acting formulations. As upstream procurement costs shifted, manufacturers reassessed sourcing strategies and nearshoring options to mitigate exposure to trade policy volatility and to maintain predictable production schedules.

These tariff-driven cost pressures accelerated conversations about vertical integration for critical components, fostering partnerships between drug developers and component suppliers that prioritize supply continuity and quality assurance. In parallel, firms revisited distribution footprints, weighing the relative efficiency of centralized manufacturing against regional fill-and-finish operations to reduce cross-border movement of finished products and thereby minimize tariff impacts.

Health system purchasers and formularies adapted contracting approaches by emphasizing value-based arrangements and multi-year supply commitments that provide predictability for both buyers and manufacturers. The cumulative effect has been a recalibration of procurement, manufacturing location decisions, and strategic sourcing models, highlighting the need for agile commercial planning that internalizes trade policy as a persistent variable rather than a transient disruption.

Comprehensive segmentation intelligence revealing how product type, mechanism, therapy focus, dosing cadence, channel, patient cohort, and regimen choices shape development and commercialization

Segmentation insights for long-acting anti-HIV products reveal differentiated clinical and commercial pathways that require tailored development and go-to-market approaches. Product type distinctions between implants and injectables drive divergent considerations: implants present choices between biodegradable and non-biodegradable matrices with implications for removal procedures and device surveillance, while injectables require formulation optimization for intramuscular or subcutaneous delivery and influence clinic-based versus community-based administration models. Mode of action segmentation illustrates how integrase inhibitors, protease inhibitors, and reverse transcriptase inhibitors each bring unique resistance profiles, interaction risks, and formulation constraints that shape combination versus monotherapy strategies.

Therapy area classification into prevention and treatment delineates distinct stakeholder value propositions and trial designs; prevention products often emphasize tolerability and long-term safety in otherwise healthy populations, whereas treatment-focused options stress virologic suppression durability and co-morbidity management. Variability in dosing frequency-bi-monthly, monthly, and quarterly-creates strategic trade-offs between patient convenience, adherence monitoring, and clinic visit cadence, necessitating different support programs and patient engagement models. Distribution channel segmentation across hospital pharmacy, online pharmacy, and retail pharmacy influences access pathways and reimbursement mechanisms, while patient type distinctions between adult and pediatric populations demand separate pediatric formulation development, dosing studies, and caregiver-focused adherence supports. Lastly, treatment regimen segmentation into combination and monotherapy frameworks, with combination options further distinguished by two-drug or three-drug regimens, drives complexity in pharmacokinetic compatibility studies and regulatory strategies, and informs commercial differentiation and positioning.

Region-specific dynamics and implementation considerations that determine how long-acting anti-HIV interventions are regulated, adopted, and scaled across diverse healthcare systems

Regional dynamics in the adoption and deployment of long-acting anti-HIV therapies reflect heterogeneous health system structures, regulatory pathways, and epidemiologic priorities. In the Americas, investment in clinic infrastructure and payer willingness to support novel administration modalities have enabled accelerated uptake in urban centers, while public health programs focus on integrating long-acting options into existing prevention and treatment initiatives. Europe, Middle East & Africa present a wide spectrum of pathways to access: regulatory harmonization efforts and national procurement strategies coexist with significant variability in healthcare delivery capacity, creating both opportunities for targeted rollouts and challenges around equitable distribution.

Asia-Pacific markets show a mix of vibrant local manufacturing capabilities, regulatory innovation in accelerated pathways, and evolving payer frameworks that influence how long-acting agents are reimbursed and distributed. Cross-region partnerships and technology transfer initiatives are increasingly important for expanding production capacity and ensuring supply resilience, with multilateral organizations playing a role in coordinating procurement and training programs. These geographic distinctions emphasize that commercial strategies must be regionally adapted, combining centralized evidence generation with localized implementation plans to address differences in healthcare delivery, regulatory expectations, and patient population needs.

Strategic competitive profiles and collaboration frameworks among developers, device partners, and manufacturing specialists that determine product momentum and commercialization readiness

The competitive and collaborative contours of the sector are shaped by an array of established pharmaceutical companies, specialist biotech innovators, and device manufacturers focused on delivery platforms. Leading developers are combining depth in antiviral pharmacology with capabilities in sustained-release technologies, and strategic alliances between drug sponsors and device engineers are common to accelerate co-development. Investment into formulation science, particularly for ensuring predictable release profiles and minimizing injection-site or implant-related complications, remains a primary differentiator among competitors.

Partnership models are also evolving; companies increasingly pursue co-development, licensing, and supply agreements to accelerate time-to-market and to de-risk manufacturing scale-up. Clinical operations partners with experience in long-duration studies and community-based delivery channels are highly valued, as are contract manufacturers capable of aseptic injectable fill-finish and implant fabrication at scale. Additionally, several firms are investing in patient support platforms, digital adherence tools, and training programs for administration to reduce barriers to uptake. Overall, firms that integrate technical excellence with pragmatic commercialization capabilities-such as robust distribution networks and payer engagement strategies-are best positioned to translate clinical advances into sustained clinical and commercial traction.

Actionable, cross-functional priorities for developers and commercial leaders to ensure resilient supply chains, payer alignment, and patient-centric adoption of long-acting therapies

Industry leaders should advance a set of pragmatic, actionable initiatives to convert scientific progress into durable clinical impact and commercial success. First, prioritize integrated development plans that align formulation, device engineering, and regulatory strategy from early stages to minimize later-stage changes and to streamline approval pathways. Second, invest in flexible manufacturing and dual-sourcing strategies to build resilience against policy-driven supply disruptions and to support regional launch plans. Third, design differentiated patient support models that adapt to dosing frequency and administration setting, ensuring both adult and pediatric cohorts receive tailored education and monitoring.

Fourth, engage payers and health systems early to articulate value propositions that reflect reduced adherence burdens, potential downstream cost offsets, and population health benefits. Fifth, pursue strategic alliances for distribution and last-mile delivery, leveraging hospital, retail, and online pharmacy networks to broaden access while maintaining cold chain and administration quality. Sixth, incorporate real-world evidence frameworks into post-approval plans to demonstrate long-term safety, adherence impact, and comparative effectiveness across prevention and treatment populations. By executing these steps in parallel, leaders can reduce time-to-impact and foster adoption pathways that align clinical benefit with sustainable commercial models.

Rigorous qualitative and document-based methodology integrating stakeholder interviews, clinical literature, and policy analysis to derive actionable strategic insights and limitations

The research underpinning this analysis combined a systematic review of contemporary clinical literature, regulatory guidance documents, and public policy statements with targeted expert consultations across development, manufacturing, and payer domains. Primary inputs included interviews with clinicians experienced in long-acting administration, regulatory affairs specialists focused on device-drug combinations, and supply chain executives overseeing regional manufacturing footprints. These qualitative engagements were complemented by secondary analysis of published safety and pharmacokinetic studies, regulatory filings, and product lifecycle disclosures to ensure alignment between clinical evidence and strategic implications.

Methodologically, triangulation was used to validate insights, reconciling divergent perspectives across stakeholders and corroborating operational implications with documented clinical outcomes. Where appropriate, scenario-based analysis was applied to evaluate the effects of tariff adjustments and distribution channel shifts on procurement and launch strategies. Limitations of the methodology are acknowledged, particularly where emerging clinical data remain immature; in such cases, recommendations emphasize adaptive planning and iterative evidence generation to inform decision-making as new data become available.

A synthesis of clinical promise and system-level imperatives that explains how coordinated industry and health system actions will determine the real-world success of long-acting therapies

Long-acting anti-HIV therapies are reshaping clinical strategy by offering new modalities to address adherence, reduce visit frequency, and sustain therapeutic effect across prevention and treatment populations. The intersection of formulation innovation, device evolution, and evolving reimbursement models has created both opportunity and complexity: manufacturers must balance pharmacologic performance with delivery practicality, while health systems must adapt infrastructure and payer constructs to support broader adoption. Across regions, tailored implementation strategies are essential to translate clinical promise into realized public health benefit.

Manufacturers and health system leaders should therefore approach the field with an integrated mindset that aligns clinical development, manufacturing resilience, market access planning, and patient support ecosystems. Where policy or tariff volatility exists, building operational flexibility is critical. Ultimately, the potential of long-acting therapies to improve adherence and outcomes will be realized through coordinated efforts across clinical, commercial, and public health stakeholders that prioritize equitable access and sustainable delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting Anti-HIV Drugs Market, by Product Type

• 8.1. Implant
  • 8.1.1. Biodegradable
  • 8.1.2. Non-Biodegradable
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Subcutaneous

9. Long-acting Anti-HIV Drugs Market, by Mode Of Action

• 9.1. Integrase Inhibitor
• 9.2. Protease Inhibitor
• 9.3. Reverse Transcriptase Inhibitor

10. Long-acting Anti-HIV Drugs Market, by Therapy Area

• 10.1. Prevention
• 10.2. Treatment

11. Long-acting Anti-HIV Drugs Market, by Dosing Frequency

• 11.1. Bi-Monthly
• 11.2. Monthly
• 11.3. Quarterly

12. Long-acting Anti-HIV Drugs Market, by Treatment Regimen

• 12.1. Combination
  • 12.1.1. Three Drug Regimen
  • 12.1.2. Two Drug Regimen
• 12.2. Monotherapy

13. Long-acting Anti-HIV Drugs Market, by Patient Type

• 13.1. Adult
• 13.2. Pediatric

14. Long-acting Anti-HIV Drugs Market, by Distribution Channel

• 14.1. Offline
• 14.2. Online

15. Long-acting Anti-HIV Drugs Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Long-acting Anti-HIV Drugs Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Long-acting Anti-HIV Drugs Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. United States Long-acting Anti-HIV Drugs Market

19. China Long-acting Anti-HIV Drugs Market

20. Competitive Landscape

• 20.1. Market Concentration Analysis, 2025
  • 20.1.1. Concentration Ratio (CR)
  • 20.1.2. Herfindahl Hirschman Index (HHI)
• 20.2. Recent Developments & Impact Analysis, 2025
• 20.3. Product Portfolio Analysis, 2025
• 20.4. Benchmarking Analysis, 2025
• 20.5. Accord Healthcare Inc.
• 20.6. Amneal Pharmaceuticals, Inc.
• 20.7. Aurobindo Pharma Ltd.
• 20.8. Cipla Ltd.
• 20.9. Dr. Reddy's Laboratories Ltd.
• 20.10. Genentech, Inc.
• 20.11. Gilead Sciences, Inc.
• 20.12. Hetero Labs Limited
• 20.13. Johnson & Johnson
• 20.14. Lupin Limited
• 20.15. Merck & Co., Inc.
• 20.16. Mylan N.V.
• 20.17. Sun Pharmaceutical Industries Ltd.
• 20.18. Teva Pharmaceutical Industries Ltd.
• 20.19. Theratechnologies Inc.
• 20.20. Viatris Inc.
• 20.21. ViiV Healthcare Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 14. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 15. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 79. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 80. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 81. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 82. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 83. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 84. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 85. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 86. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 87. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 88. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 89. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 90. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 92. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 93. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 94. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 95. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 96. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 97. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 98. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 99. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 100. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 101. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 103. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 104. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 105. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 106. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 107. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 108. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 109. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 110. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 111. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 119. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 120. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 123. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 125. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 126. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 127. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 128. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 129. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 130. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 131. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 132. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 133. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 134. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 136. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 137. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 138. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 139. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 140. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 141. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 142. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 143. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 144. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 145. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 146. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 147. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 148. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 149. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 150. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 151. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 152. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 153. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 154. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 155. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 156. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 157. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 158. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 159. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 160. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 161. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 162. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 163. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 164. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 165. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 166. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 167. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 168. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 169. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 170. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 171. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 172. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 173. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 174. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 175. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 176. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 177. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 178. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 179. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 180. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 181. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 182. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 183. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 184. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 185. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 186. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 187. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 188. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 189. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 190. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 191. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 192. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 193. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 194. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 195. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 196. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 197. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 198. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 199. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 200. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 201. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 202. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 203. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 204. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 205. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 206. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 207. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 208. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 209. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 210. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 211. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 212. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 213. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 214. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 215. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 216. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 217. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 218. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 219. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 220. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 221. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 222. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 223. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 224. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 225. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 226. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 227. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 228. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 229. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 230. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 231. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 232. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 233. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 234. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 235. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 236. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 237. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 238. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 239. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 240. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 241. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 242. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 243. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 244. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 245. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 246. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 247. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 248. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 249. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 250. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 251. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 252. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 253. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 254. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 255. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 256. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)